BD Veritor System Infectious Disease Immunoassay SARS-CoV-2 Nasal


Packaging: 1/EA

Product SKU: BD-256082

Shipping: Free Shipping

This item qualifies for FREE Shipping on orders over $100

Availability: 0 in stock
Price: $649.00$
Cart New
BD Veritor Plus System for rapid COVID-19 (SARS-CoV-2) testing
The portable, easy-to-use BD Veritor Plus System provides reliable COVID-19 (SARS-CoV-2) results in 15 minutes
*See Our Full Disclaimer

The BD Veritor System for Rapid Detection of SARS-CoV-2 is a chromatographic immunoassay for the direct and qualitative detection of SARS-CoV-2 antigens in nasal swabs from patients with signs and symptoms who are suspected of COVID-19.


Simplify the testing process

  • Easy operation and 1-button functionality may help reduce manual test processing errors
  • Simple sample processing with color-coded tubes

Achieve fast, reliable results

  • Displays easy-to-read digital results for COVID-19 in 15 minutes: “CoV2: +” for positive, “CoV2: -” for negative
  • Records results on secured internal drive
  • Advanced particle technology helps improve test performance*

Provide workflow efficiency

  • Adapts easily to your workflow by offering 2 operational modes
    - Walk away: Test device is inserted immediately into Analyzer, so staff can multi-task while sample incubates (15 minutes)
    - Analyze now: Test device is inserted after incubation time is complete, allowing batches of samples to be tested (results in seconds)

Provide result traceability

  • Download and display Lot number, patient/specimen ID, Operator ID and test records with BD Veritor InfoScan module
  • Offers result-printing capabilities via USB port

 *in comparison to visually read tests

FDA Disclaimers:

  • This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories
  • This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and
  • This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.